FATE Fate Therapeutics, Inc.
Legal ·
The 10-Q says Fate and unnamed officers are defendants in a Southern District of California class action. The derivative suits are captioned against Wolchko; board lists come from Fate's 2023 and 2026 proxies.
Fate Therapeutics (Nasdaq: FATE) expects $0.9 million to $1.2 million in severance charges in the third quarter of 2025. The company says it has $249 million in cash and investments and a runway through the end of 2027.
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies. Its platform creates and engineers induced pluripotent stem cells, or iPSCs, into clonal master iPSC lines that serve as a renewable source for manufacturing uniform, multiplexed-engineered T-cell and natural killer cell product candidates. The company says this approach addresses the limits of autologous cell therapies and of viral vectors used to deliver genetic information into patients' T cells. It operates a 40,000+ square foot GMP facility intended to support clinical development and initial commercialization, and it reports over 600 issued patents and 550 pending patent applications for its iPSC platform. Its strategy is to bring these therapies first to patients with autoimmune diseases and cancer. The lead autoimmune program is FT819, an off-the-shelf, iPSC-derived, CD19-targeted CAR T-cell candidate for systemic lupus erythematosus with and without lupus nephritis. A multi-center Phase 1 trial is underway at sites in the United States, the United Kingdom and the European Union, and the FDA granted FT819 regenerative medicine advanced therapy designation in April 2025.
| Product or program | What it is | Stage |
|---|---|---|
| FT819 | Off-the-shelf iPSC-derived CD19-targeted CAR T-cell therapy for systemic lupus erythematosus | Phase 1; RMAT designation granted April 2025 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $6.6 million | $13.6 million |
| Research and development | $107.8 million | $135.0 million |
| Net income (loss) | -$136.3 million | -$186.3 million |
| Cash from operations | -$106.1 million | -$122.9 million |
| Cash and equivalents | $46.6 million | $36.1 million |
| Short-term investments | $157.0 million | $243.0 million |
Our latest story on this, dated Aug 13, 2026: "Fate Therapeutics faces securities class action and three derivative suits over Janssen disclosures". The story links the filing or release it is based on. Read the story.
Fate Therapeutics, Inc. trades under the ticker FATE on NASDAQ.
Fate Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:F6T; LS:A1W50M; LSX:A1W50M.
The SEC Central Index Key (CIK) for Fate Therapeutics, Inc. is 1434316. Its filings are on SEC EDGAR.
119,820,514 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Fate Therapeutics, Inc. under United States.
Our directory classifies Fate Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Fate Therapeutics, Inc. is US31189P1021.
aibio.space lists Fate Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies. Its platform creates and engineers induced pluripotent stem cells, or iPSCs, into clonal master iPSC lines that serve as a renewable source for manufacturing uniform, multiplexed-engineered T-cell and natural killer cell product candidates.
FT819: Off-the-shelf iPSC-derived CD19-targeted CAR T-cell therapy for systemic lupus erythematosus Stage: Phase 1; RMAT designation granted April 2025.
$6.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Fate Therapeutics, Inc. reported a net loss of $136.3 million for the fiscal year ended Dec 31, 2025, and used $106.1 million of cash in operations, per its annual report to the SEC.
$107.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$153.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio